Klinická farmakologie a farmacie – 1/2021

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2021; 35(1): 24–28 / www.klinickafarmakologie.cz 28 HLAVNÍ TÉMA Analytické metody pro stanovení cefazolinu 8. Trent Magruder J, Grimm JC, Dungan SP, Shah AS, Crow JR, Shoulders BR, Lester L, Barodka V. Continuous Intraoperative Cefazolin Infusion May Reduce Surgical Site Infections During Cardiac Surgical Procedures: A Propensity-Matched Analysis. J Cardiothor Vas An. 2015; 29(6): 1582–1587. 9. SPC Cefazolin, Summary of Product Characteristics: https:// www.sukl.cz/modules/medication/detail.php?kod=0221885 (accessed on Jan. 05, 2021). 10. McCracken Jr GH, Nelson JD. Antimicrobial Therapy for Newborns. 2 nd ed. New York: Grune & Stratton, 1983. ISBN 9781610023184. 11. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013; 70(3): 195–283. 12. van Kralingen S, Taks M, Diepstraten J, van de Garde EM, van Dongen EP, Wiezer MJ, van Ramshorst B, Vlaminckx B, Deneer VH, Knibbe CA. Pharmacokinetics and protein bin‑ ding of cefazolin in morbidly obese patients. Eur J Clin Phar‑ macol. 2011; 67: 985–992. 13. Caro YS, Camara MS, De Zan MM. A Review Of Bioanalyti‑ cal Methods For The Therapeutic Drug Monitoring Of Beta‑ -Lactam Antibiotics In Critically Ill Patients: Evaluation Of The Approaches Used To Develop And Validate Quality Attribu‑ tes. Talanta. 2020; 210: 12. 14. Nováková L, Douša M, Blatný P, et al. Moderní HPLC se‑ parace v teorii a praxi I. Praha: Europrint, a. s., 2013. ISBN 978- 80-260-4244-0. 15. Carlier M, Stove V, Wallis SC, et al. Assays For Therapeutic Drug Monitoring Of Beta-Lactam Antibiotics: A Structured Review. Int J Antimicrob Ag. 2015; 46: 367–375. 16. Dorn C, Kratzer A, Schiesser S, Kees F, Wrigge H, Simon P. Determination of total or free cefazolin and metronidazole in human plasma or interstitial fluid by HPLC-UV for pharma‑ cokinetic studies in man. J Chromatogr B. 2019; 1118: 51–54. 17. Crutchfield CA, Marzinke MA. Bioanalytical develop‑ ment and validation of liquid chromatographic-tandem mass spectrometric methods for the quantification of total and free cefazolin in human plasma and cord blood. Pract Lab Med. 2015; 1: 12–21. 18. Bellouard R, Deslandes G, Morival C, Li J, Boutoille D, Jolliet P, Dailly E, Gregoire M. Simultaneous determination of eight beta-lactam antibiotics in human plasma and cerebrospi‑ nal fluid by liquid chromatography coupled to tandemmass spectrometry. J Pharmaceut Biomed. 2020; 178: 8. 19. Ohmori T, Suzuki A, Niwa T, Ushikoshi H, Shirai K, Yoshida S, Ogura S, Itoh Y. Simultaneous determination of eight be‑ ta-lactam antibiotics in human serum by liquid chromato‑ graphy-tandem mass spectrometry. J Chromatogr B. 2011; 879: 1038–1042. 20. Sime F, Roberts MS, Roberts JA, Robertson TA. Simultane‑ ous determination of seven beta-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokine‑ tic studies. J Chromatogr B. 2014; 960: 134–144. 21. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JPJ. Analysis of 12 beta-lactam antibiotics in hu‑ man plasma by HPLC with ultraviolet detection. J Chroma‑ togr B. 2010; 878: 2039–2043. 22. Colin P, De Bock L, T’Jollyn H, Boussery K, Van Bocxlaer J. Development and validation of a fast and uniform appro‑ ach to quantify beta-lactam antibiotics in human plasma by solid phase extraction-liquid chromatography-electro‑ spray-tandemmass spectrometry. Talanta 2013; 103: 285–293. 23. Briscoe SE, McWhinney BC, Lipman J, Roberts JA, Ungerer JPJ. A method for determining the free (unbound) concent‑ ration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet de‑ tection. J Chromatogr B. 2012; 907: 178–184. 24. Carlier M, Stove V, Roberts JA, Van de Velde E, De Wae‑ le JJ, Verstraete AG. Quantification of seven beta-lactam an‑ tibiotics and two beta-lactamase inhibitors in human plas‑ ma using a validated UPLC-MS/MS method. Int J Antimicrob Ag. 2012;40, 416–422. 25. Omar MA, Abdelmageed OH, Attia TZ. Kinetic spectro‑ fluorimetric determination of certain cephalosporins in hu‑ man plasma. Talanta 2009; 77: 1394–1404. 26. Brozmanová H. Laboratorní metody v terapeutickém monitorování léků. Klin Farmakol Farm 2020; 34(2): 56–62. 27. Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lip‑ man J, Roberts JA. Protein Binding of Beta-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations? Antimicrob Agents Ch. 2013; 57: 6165–6170. 28. Kratzer A, Liebchen U, Schleibinger M, Kees MG, Kees F. Determination of free vancomycin, ceftriaxone, cefazolin and ertapenem in plasma by ultrafiltration: Impact of experimen‑ tal conditions. J Chromatogr B. 2014; 961: 97–102. 29. Vuignier K, Schappler J, Veuthey JL, Carrupt PA, Martel S. Drug-protein binding: a critical review of analytical tools. Anal Bioanal Chem. 2010; 398: 53–66. 30. Rehm S, Rentsch KM. LC-MS/MS method for nine different antibiotics. Clin Chim Acta. 2020; 511: 360–367. 31. Roberts JA, Pea F, Lipman J. The Clinical Relevance Of Plasma Protein Binding Changes. Clin Pharmacokinet. 2013; 52: 1–8. 32. Vella-Brincat JWA, Begg EJ, Kirkpatrick CMJ, Zhang M, Chambers ST, Gallagher K. Protein binding of cefazolin is sa‑ turable in vivo both between and within patients. Brit J Clin Pharmaco. 2007; 63: 753–757.